Abstract:Objective To investigate the indications,complications and prognosis of chimeric antigen receptor T cells (CAR-T)in the treatment of relapsed/refractory primary central nervous system lymphoma (PCNSL).Methods On May 21,2015,one patient with relapsed/refractory PNCSL admitted to the Department of Hematology,Xuzhou Medical University Affiliated Hospital was selected as the study object. The peripheral blood lymphocytes of the patient were collected by blood cell apheresis,and humanized CD19 and CD20 CAR-T were prepared.CAR is stably expressed in CD3+ T cells via lentiviral vector.On July 27, 2017,the patient received FC regimen of conditioning regimen by fludarabine 30 mg/(m2 ·d),d-5 to-3,and cyclophosphamide 750 mg/(m2 ·d),d-5.Humanized CD19 and CD20 CAR-T were transfused with dose of 1×106/kg each,on the first day after conditioning regimen.The clinical features and diagnosis of the patient were summarized by retrospective analysis.This study was in line with World Medical Association Declaration of Helsinki revised in 2013 and informed contents of clinical research and CAR-T immunotherapy were obtained from the subject.Results ① The patient was male and 45 years old.In February 2015,the patient appeared headache,dizziness,and blindness in the right eye without obvious incentives.In March 2015,the patient was diagnosed with diffuse large B-cell lymphoma based on his pathology and immunohistochemistry results.In January 2016,the patient achieved unconfirmed complete remission (CRu)after surgical removal of the corpus callosum,radiotherapy,and high-dose radiation therapy.In March 2017,the patient's primary disease recurred,but the condition was relieved after receiving temozolomide+high-dose methotrexate (HD-MTX)chemotherapy.② After 10 d of CAR-T infusion,the patient's headache symptoms were significantly reduced and the orientation was recovery. Grade 1 cytokine release syndrome(CRS)occurred during treatment.Patient's symptoms improved after he received symptomatic supportive treatment.After 29,69 and 116 d of CAR-T transfusion,the results of patient's head-enhanced MRI showed that the primary lesion continued to shrink.And the patient reached partial remission (PR).After 69 and 116 d of CAR-T transfusion,CAR-T were detected in cerebrospinal fluid flow cytometry of patient.After 154 d of CAR-T transfusion,the patient returned to hospital for treatment,due to "left limb weakness".Re-examination of head-enhanced MRI showed recurrence of primary disease.Then the patient received salvage treatment of high-dose chemotherapy.As of July 2019, the patient was still receiving temozolomide + HD-MTX chemotherapy for maintenance treatment. Conclusions As a new treatment regimen,CAR-T immunotherapy could be used as a salvage bridging treatment in the treatment of patients with relapsed/refractory PCNSL.And it is still necessary to maintain and consolidate the treatment.However,the above conclusions are based on one case study,and the maintenance treatment of patients with relapsed/refractory PCNSL after CAR-T immunotherapy,such as the time of maintenance treatment beginning ,as well as the maintenance treatment regimen,still need to be further explored.

Case report: Bridging radiation therapy before chimeric antigen receptor T-cell therapy induces sustained remission in patients with relapsed/refractory double-expressor diffuse large B-cell lymphoma with localized compressive symptoms

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: an Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

On Route to Chimeric Antigen Receptor T-cell (CAR T) Therapy, Less Is More: Adaptive Bridging Radiotherapy in Large B-cell Lymphoma

Case Report: Deep Molecular Remissions Post Two Separate CD19-targeted Chimeric Antigen Receptor T-cell Therapies Do Not Prevent Disease from Relapsing in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Hyper-fractionated Radiotherapy As a Bridging Strategy to Enhance CAR-T Efficacy by Regulating T-cell Co-Stimulatory Molecules in Relapsed/refractory Diffuse Large B-cell Lymphoma

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease

Clinical Analysis of Chimeric Antigen Receptor T Cells Immunotherapy in Treatment of One Patient with Relapsed/refractory Primary Central Nervous System Lymphoma

Lymphodepletion Chemotherapy Revitalizes Chimeric Antigen Receptor T Cells Contributing to Regression of Relapsed B-cell Lymphoma A Case Report

Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes

CAR T-cell Therapy Combined with Autologous Hematopoietic Cell Transplantation in Patients with Refractory/relapsed Burkitt Lymphoma

Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy

Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma